Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — 43rd Annual J.P. Morgan Healthcare Conference 2025
21 slides from Quidelortho's conference presentation, Jan 13, 2025
Slide 1: J.P. Morgan 43rd Annual Healthcare Conference
January 13, 2025 J.P. Morgan 43rd Annual Healthcare Conference Brian Blaser President & Chief Executive Officer
Slide 2: Forward-looking Statements and Non-GAAP Financial Measures
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 2 Forward-looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) contains “forward-looking statements” within the meaning of
Slide 3: About Us
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 3 About Us 80+ Years ~$50B Total Addressable Market Advancing ~$20B the Power IVD Markets Served of Diagnostics for a Healthier 330+ Products Future for All $2.78B FY 2024 Preliminary Nasdaq: QDEL Reported Revenue1 (Unaudited)
Slide 4: Global In Vitro Diagnostics Company
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 4 Global In Vitro Diagnostics Company Three global commercial regions spanning 130+ countries North Pencoed, Wales America Rochester, NY 59%1 Raritan, NJ San Diego, CA Pompano Beach, FL Hunan, China JPAC/China EMEA/Latin 21%1 A
Slide 5: Leadership Team
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 5 Leadership Team Brian Blaser President and Chief Executive Officer Joseph Busky Chief Financial Officer Lee Bowman Chief Human Resources Officer Michelle Hodges Chief Legal Officer Phil McLellan Chief Operations Officer Jonat
Slide 6: Diagnostic Portfolio Across the Continuum of Care
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 6 Diagnostic Portfolio Across the Continuum of Care Products for every care setting and every stage of the patient journey Reference Labs Hospitals Ambulatory Clinics & Specialty Settings Retail Home Free Sexual Reference IDN C
Slide 7: Leading Global Portfolio in Large, Growing Markets
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 7 Leading Global Portfolio in Large, Growing Markets Serving over 1 million patients every day Labs Point of Care $30B Market Size $9B Market Size BUSINESS UNITS Transfusion Molecular Medicine Diagnostics $3B Market Size $9B Ma
Slide 8: Labs
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 8 Labs Strong Global Customer Base with Long-term Contracts Standardized & Scalable Waterless Systems Lowest Total Cost of Ownership $1.1B ~15,000 MSD YTD Q3’24 Worldwide Cumulative Projected Annual Growth Rate1 Revenue Placeme
Slide 9: Transfusion Medicine
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 9 Transfusion Medicine Global Leader in Immunohematology Full Suite of Automated Solutions Connected Informatics Ecosystem $386M ~7,400 LSD Worldwide Projected Annual YTD Q3’24 Cumulative Placements Growth Rate1 Revenue (exclud
Slide 10: Point of Care
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 10 Point of Care Fast, Lab-Quality Results at the Point-of-Care Ease of Use, No Special Training Required ~97,000 ~17,000 MSD Sofia® Worldwide Cumulative Triage® Worldwide Cumulative Projected Annual Growth Rate1 $509M Placemen
Slide 11: Molecular Diagnostics
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 11 Molecular Diagnostics Developing World-Class Syndromic Molecular Solutions Highly Accurate Results in Minutes Small Footprint, Optimized Workflow $17M YTD Q3’24 Revenue
Slide 12: Value Creation Thesis
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 12 Value Creation Thesis Durable Growth and Margin Expansion Strong Business Provides Sustainable Recurring Revenue Growing installed base in large global markets Long-term customer relationships and contracts Differentia
Slide 13: Disciplined Strategy
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 13 Disciplined Strategy Driving improved performance and value creation Delivering an Driving Prioritizing Exceptional Profitable, Effective Customer Sustainable Execution Experience Growth
Slide 14: Disciplined Strategy
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 14 Disciplined Strategy Key priorities for continuous evolution Delivering an Driving Prioritizing Exceptional Profitable, Effective Customer Sustainable Execution Experience Growth Operate at highest levels Improve cost st
Slide 15: Full-Year 2024 Financial Guidance
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 15 Full-Year 2024 Financial Guidance1 Financial Guidance2 FY 2024 (as of November 7, 2024) $2.75B–$2.80B $530M–$550M 19.3%–19.6% $1.69–$1.91 Total Revenues (reported) Adjusted EBITDA Adjusted EBITDA Margin Adjusted Diluted EPS
Slide 16: Cash Flow and Balance Sheet
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 16 Cash Flow and Balance Sheet Balance Sheet Q3 2024 Cash Flow1 (as of September 29, 2024) $120M $41M $144M ~4.1x QTD Adjusted Free YTD Adjusted Free Net Debt to Cash Cash Flow2 Cash Flow3 Adjusted EBITDA4 $46M $144M $2.6B ~3.3
Slide 17: Capital Allocation Priorities
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 17 Capital Allocation Priorities Menu expansion into fastest growing, most profitable market segments Build Sustainable, Complete integration, i.e., ERP, IT infrastructure Profitable Growth Prudently manage balance sheet,
Slide 18: Focused on Margin Expansion
QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 18 Focused on Margin Expansion Significant margin expansion drivers over 2-3 years Mid- to high-20% Adj. EBITDA Margin FY’24 19.5% Adj. EBITDA Margin (mid-point of guidance range) Molecular Diagnostics Operational Growth Effici
Slide 19: Value Creation Thesis
QuidelOrtho – Proprietary & Confidential. | © 2024. All Rights Reserved. 19 Value Creation Thesis Durable Growth and Margin Expansion Strong Business Provides Sustainable Recurring Revenue Growing installed base in large global markets Long-term customer relationships and contracts Differentia
Slide 20: QuidelOrtho
@® QuidelOrtho
Slide 21: quidelortho.com
quidelortho.com
QuidelOrtho — 43rd Annual J.P. Morgan Healthcare Conference 2025 on 6ix